A Bulletproof Clinical Evaluation Report: Making them stand up to regulatory scrutiny

แชร์
ฝัง
  • เผยแพร่เมื่อ 27 ก.ย. 2024

ความคิดเห็น • 1

  • @Tenneisa
    @Tenneisa 2 ปีที่แล้ว

    Hi. Thank you so much for this video, super insightful. If the company is not claiming for equivalence AND they don't have post-market data, should we still include a discussion on post-market data for an equivalent device in our SOTA?